DK0835138T3 - Præparat til diagnosticering af metabolisk syndrom og sygdomme relateret til dette syndrom - Google Patents

Præparat til diagnosticering af metabolisk syndrom og sygdomme relateret til dette syndrom

Info

Publication number
DK0835138T3
DK0835138T3 DK96916423T DK96916423T DK0835138T3 DK 0835138 T3 DK0835138 T3 DK 0835138T3 DK 96916423 T DK96916423 T DK 96916423T DK 96916423 T DK96916423 T DK 96916423T DK 0835138 T3 DK0835138 T3 DK 0835138T3
Authority
DK
Denmark
Prior art keywords
syndrome
diagnosis
metabolic syndrome
preparation
cortisol
Prior art date
Application number
DK96916423T
Other languages
Danish (da)
English (en)
Inventor
Per Marin
Original Assignee
Cortendo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo Ab filed Critical Cortendo Ab
Application granted granted Critical
Publication of DK0835138T3 publication Critical patent/DK0835138T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Combined Controls Of Internal Combustion Engines (AREA)
DK96916423T 1995-05-30 1996-05-30 Præparat til diagnosticering af metabolisk syndrom og sygdomme relateret til dette syndrom DK0835138T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9501991A SE505391C2 (sv) 1995-05-30 1995-05-30 Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet
PCT/SE1996/000708 WO1996038179A1 (en) 1995-05-30 1996-05-30 Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome

Publications (1)

Publication Number Publication Date
DK0835138T3 true DK0835138T3 (da) 2003-07-21

Family

ID=20398470

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96916423T DK0835138T3 (da) 1995-05-30 1996-05-30 Præparat til diagnosticering af metabolisk syndrom og sygdomme relateret til dette syndrom

Country Status (16)

Country Link
US (1) US6410339B1 (sv)
EP (1) EP0835138B1 (sv)
JP (1) JPH11505850A (sv)
CN (1) CN1078479C (sv)
AT (1) ATE235258T1 (sv)
AU (1) AU716671B2 (sv)
BR (1) BR9608683A (sv)
CA (1) CA2222215A1 (sv)
DE (1) DE69626982T2 (sv)
DK (1) DK0835138T3 (sv)
ES (1) ES2189872T3 (sv)
NO (1) NO319829B1 (sv)
PT (1) PT835138E (sv)
RU (1) RU2171471C2 (sv)
SE (1) SE505391C2 (sv)
WO (1) WO1996038179A1 (sv)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217505B2 (en) * 1998-02-26 2007-05-15 Cortendo Ab Method for determining whether condition is symptom of metabolic syndrome
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
US20090117660A1 (en) * 2005-04-30 2009-05-07 Oakville Hong Kong Co., Limited Devices and methods for sample collection and analysis
CA2665164A1 (en) * 2006-10-06 2008-05-15 Nestec S.A. Compositions and multiplex assays for measuring biological mediators of physiological health
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
RU2444298C1 (ru) * 2010-07-15 2012-03-10 Учреждение Российской академии медицинских наук Научный центр клинической и экспериментальной медицины Сибирского отделения РАМН (НЦКЭМ СО РАМН) Способ диагностики метаболического синдрома
CN105973881A (zh) * 2016-04-27 2016-09-28 樊福好 一种检测机体活度的溶液及检测方法

Also Published As

Publication number Publication date
BR9608683A (pt) 1999-12-07
CA2222215A1 (en) 1996-12-05
ATE235258T1 (de) 2003-04-15
CN1078479C (zh) 2002-01-30
AU716671B2 (en) 2000-03-02
PT835138E (pt) 2003-08-29
CN1185743A (zh) 1998-06-24
WO1996038179A1 (en) 1996-12-05
EP0835138A1 (en) 1998-04-15
SE505391C2 (sv) 1997-08-18
DE69626982T2 (de) 2004-03-04
MX9709234A (es) 1998-10-31
RU2171471C2 (ru) 2001-07-27
DE69626982D1 (de) 2003-04-30
EP0835138B1 (en) 2003-03-26
NO975492D0 (no) 1997-11-28
SE9501991L (sv) 1996-12-01
SE9501991D0 (sv) 1995-05-30
JPH11505850A (ja) 1999-05-25
AU5917396A (en) 1996-12-18
NO975492L (no) 1998-01-27
NO319829B1 (no) 2005-09-19
ES2189872T3 (es) 2003-07-16
US6410339B1 (en) 2002-06-25

Similar Documents

Publication Publication Date Title
DK0835138T3 (da) Præparat til diagnosticering af metabolisk syndrom og sygdomme relateret til dette syndrom
Wing et al. Exercise in a behavioural weight control programme for obese patients with type 2 (non-insulin-dependent) diabetes
Day et al. Concentration‐response relationships for salicylate‐induced ototoxicity in normal volunteers.
Lee et al. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice
Mooren et al. Lymphocyte apoptosis after exhaustive and moderate exercise
Saas et al. CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: a key role in brain inflammation?
Zuckerman et al. Comparison of stress effects of perceptual and social isolation
Mishra et al. Nicotine inhibits FcεRI-induced cysteinyl leukotrienes and cytokine production without affecting mast cell degranulation through α7/α9/α10-nicotinic receptors
Rosenbloom et al. Chronic overtreatment with insulin in children and adolescents
Ronis et al. Cytokine and chemokine expression associated with steatohepatitis and hepatocyte proliferation in rats fed ethanol via total enteral nutrition
Tutunchi et al. Expression of NF‐κB, IL‐6, and IL‐10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD—Combined effects of oleoylethanolamide supplementation and calorie restriction: A triple‐blind randomized controlled clinical trial
Jin et al. Responses of the ambulatory arterial stiffness index and other measures of arterial function to antihypertensive drugs
Del Pinto et al. Hypertension and periodontitis: a joint report by the Italian Society of Hypertension (SIIA) and the Italian Society of Periodontology and Implantology (SIdP)
RU97121292A (ru) Препарат для диагностики метаболического синдрома и заболеваний, включающих в себя данный синдром
Svane-Knudsen Sudden “spontaneous” lesion of aural function
Xie et al. SIRT1 activation ameliorates aldara-induced psoriasiform phenotype and histology in mice
Kobayashi et al. The anti-atherosclerotic dipeptide, Trp-His, reduces intestinal inflammation through the blockade of L-type Ca2+ channels
Huh et al. Glucose-based peritoneal dialysis solution suppresses adiponectin synthesis through oxidative stress in an experimental model of peritoneal dialysis
Muchnik et al. Effect of emotional stress on hearing
DE602004022968D1 (de) Ie behandlung mti insulinsensibilisatoren
Del Seppia et al. Evidence in hypertensive rats of hypotensive effect after mandibular extension
Alinezhad‐Namaghi et al. Association of time‐restricted feeding, arterial age, and arterial stiffness in adults with metabolic syndrome
Wang et al. Serum 25‐Hydroxyvitamin D Levels in Type 2 Diabetes Patients in North China: Seasonality and the Association between Vitamin D Status and Glycosylated Hemoglobin Levels
Harvey et al. Acute thermotherapy prevents impairments in cutaneous microvascular function induced by a high fat meal
Situmorang et al. Emotion Distress and Self-Care Behavior in Type II Diabetes Mellitus Patients in Matsum, Medan, North Sumatera